Dihexa Peptide UAE — Complete Guide to Neurogenesis, Dosage & Cognitive Benefits
Dihexa Peptide: Complete Guide to Neurogenesis, Dosage & Cognitive Benefits
Reviewed by the CoreSup Research Team · Based on Washington State University pharmacology research, PubMed-indexed studies, and peer-reviewed neuroscience literature · Updated March 2026
Dihexa is not a household name in the nootropic world — and that is precisely why it is worth your attention. While most people in cognitive enhancement circles debate the finer points of racetams and adaptogens, a small and well-informed subset have been quietly researching a compound that emerged from Alzheimer's disease research at Washington State University and is, by certain pharmacological metrics, one of the most potent pro-cognitive molecules ever studied.
The claim that makes Dihexa stand out is not a marketing one — it comes from the laboratory of Dr Joseph Harding at WSU, who reported that Dihexa is approximately ten million times more potent than BDNF (brain-derived neurotrophic factor) in promoting synaptogenesis in hippocampal tissue. That is a staggering figure. It needs context, caveats, and honest evaluation — which this guide provides. Dihexa works through a completely different mechanism than most nootropic peptides, targeting the hepatocyte growth factor (HGF) system and its receptor c-Met to promote the formation of new synaptic connections in the brain.
This guide covers the science, benefits, dosage protocols, honest risks (including the cancer question), comparison with other cognitive peptides, and how to source Dihexa in the UAE.
TL;DR: Dihexa is a synthetic hexapeptide derived from angiotensin IV, developed at Washington State University for Alzheimer's research. It works via the HGF/c-Met pathway to promote synaptogenesis — the formation of new synaptic connections. Reported as ~10 million times more potent than BDNF in promoting synaptogenesis in vitro. Available as oral capsules or transdermal cream. Standard research dose: 10–30 mg orally or 10–15 mg transdermally. Long-acting (estimated days-long half-life). Requires careful cycling due to HGF pathway risks at high doses. Legal research compound in the UAE.
Looking for research-grade Dihexa in the UAE? Browse the CoreSup peptides collection — third-party tested with full certificates of analysis, delivered across the UAE.
What Is Dihexa?
Dihexa is the common name for the research compound N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — a synthetically designed hexapeptide derived from angiotensin IV, a fragment of the renin-angiotensin system. Its development began in the laboratory of Dr Joseph W. Harding at Washington State University as part of a systematic programme to develop treatments for cognitive impairment associated with Alzheimer's disease and other neurodegenerative conditions.
Angiotensin IV had previously been shown to improve spatial memory in rodent models, but it was metabolically unstable and could not cross the blood-brain barrier efficiently. The Harding laboratory created a series of truncated, modified analogues to overcome these limitations. Dihexa was the compound that emerged from this process — a peptidomimetic molecule engineered for enhanced bioavailability, metabolic stability, and central nervous system penetration.
Dihexa has not progressed to human clinical trials under its current form. A closely related pro-drug, Fosgonimeton (ATH-1017), developed by Athira Pharma, has entered Phase 2/3 clinical trials for Alzheimer's — confirming that the HGF/c-Met pathway Dihexa targets is considered a legitimate therapeutic avenue by the broader pharmaceutical industry.
How Dihexa Works: The HGF/c-Met Pathway and Synaptogenesis
To understand Dihexa, you need to understand what hepatocyte growth factor (HGF) does in the brain. Despite its name suggesting a liver function, HGF and its receptor c-Met are expressed throughout the central nervous system and play a critical role in neuronal survival, axonal growth, and — most relevantly — synaptogenesis: the formation of new synapses between neurons.
Synapses are the connections through which neurons communicate. Learning and memory formation depend on the establishment, strengthening, and refinement of synaptic networks. In conditions like Alzheimer's disease, synapse loss precedes and predicts cognitive decline more strongly than amyloid plaques or tau tangles. A compound that promotes synaptogenesis is therefore addressing a core mechanism of cognitive deterioration.
Dihexa activates c-Met receptors, triggering a signalling cascade that promotes the sprouting of dendritic spines and the formation of functional synaptic connections. Unlike BDNF — which is a large protein that cannot easily cross the blood-brain barrier — Dihexa is a small, lipophilic peptidomimetic that crosses the blood-brain barrier efficiently. This is why it demonstrates such extraordinary potency relative to BDNF in the synaptogenesis assay: it gets to where BDNF cannot.
Key Mechanisms
- HGF/c-Met activation: Primary mechanism. Promotes synaptogenesis and dendritic spine formation in the hippocampus and cortex.
- Neuroplasticity enhancement: Increases the brain's ability to form and reorganise synaptic connections in response to experience.
- Neuroprotection: HGF/c-Met signalling activates cell-survival pathways (PI3K/Akt) that protect neurons from apoptotic death.
- Hippocampal function: Animal studies show specific improvements in hippocampal-dependent spatial memory and learning tasks.
Dihexa Benefits: Research Evidence
1. Synaptogenesis and Structural Brain Improvement
This is Dihexa's defining characteristic. While most nootropics improve neurochemistry (neurotransmitter levels, receptor sensitivity), Dihexa promotes the physical formation of new synaptic connections. This is a structural change, not just a functional one — and it is why the compound's effects are often described as long-lasting and cumulative rather than acute and transient.
2. Spatial Memory and Learning
The most replicated finding in Dihexa animal research is improvement in spatial memory tasks, particularly the Morris Water Maze — a standard test of hippocampal-dependent memory. Aged animals (with cognitive impairment equivalent to mild-to-moderate Alzheimer's) showed performance returning to youthful levels after Dihexa treatment. The 2013 McCoy paper reported effects equivalent to reversing ~50% of age-related cognitive decline in this model.
3. Alzheimer's Disease Research
Dihexa was developed specifically for Alzheimer's disease, and the pathological context gives its benefits their most dramatic expression. In Alzheimer's, synapse loss is the strongest correlate of cognitive decline — more so than amyloid burden. Dihexa's synaptogenic mechanism directly addresses this. The compound is not in human trials for Alzheimer's directly, but Athira Pharma's Fosgonimeton — a pro-drug of a Dihexa analogue — has completed Phase 2 trials in mild-to-moderate Alzheimer's patients.
4. Neuroplasticity and Learning Acceleration
Beyond disease contexts, Dihexa's synaptogenic activity theoretically supports enhanced learning in healthy individuals by increasing the brain's capacity to form new synaptic networks. This is distinct from stimulant effects — it is not increasing arousal or motivation, but potentially increasing the structural substrate available for memory encoding.
5. Depression and Mood
HGF/c-Met signalling in the hippocampus has been linked to antidepressant effects in animal models. Some Dihexa users report improvements in mood and reduced anhedonia, though this is less consistently reported than cognitive effects and less well-studied.
Dihexa Side Effects and the Cancer Risk Question
The HGF/c-Met Cancer Concern
HGF and its receptor c-Met are well-established oncology targets. Aberrant c-Met activation is associated with tumour growth, invasion, and metastasis in a number of cancers (lung, gastric, renal, liver). Several pharmaceutical companies have developed c-Met inhibitors as cancer therapies — meaning the pathway Dihexa activates is also a pathway that, when overactivated in cancer cells, promotes disease progression.
The critical question is: does Dihexa's activation of c-Met at research dosing levels meaningfully increase cancer risk in healthy tissue? The honest answer is: we do not know with certainty in humans. No human trials with Dihexa have been conducted, and long-term carcinogenicity studies are lacking. Animal studies have not shown tumour promotion at typical research doses, and the HGF/c-Met pathway in healthy tissue has a different regulatory context than in malignant tissue. But the risk cannot be mathematically excluded.
Practical implications:
- Individuals with a personal or family history of cancer — particularly cancers with known c-Met involvement (lung, gastric, renal, hepatocellular) — should not use Dihexa without specialist medical review.
- Dose and cycle moderation is more important with Dihexa than with lower-risk nootropics.
- Long continuous use protocols should be avoided.
Reported Side Effects (Non-Cancer)
- Cognitive overstimulation: At high doses, some users report mental overstimulation, difficulty "turning off" thoughts, or increased anxiety. Usually dose-dependent and resolves with reduction.
- Sleep disruption: The long half-life means late-day dosing can affect sleep quality. Morning-only administration is recommended.
- Headache: Occasional, particularly in the first 1–2 uses. Typically mild.
- Mood changes: Minor mood variability reported by some users, typically in the first week of use.
What Dihexa Does NOT Cause
Dihexa is not androgenic, not estrogenic, not a stimulant, and not cardiovascularly active at research doses. It does not suppress endogenous hormone production. The side-effect profile at standard doses is mild — the cancer pathway concern is theoretical, not documented in observed adverse events.
Dihexa Dosage Protocol
Available Forms
Dihexa is available in the research peptide market in two primary forms:
- Oral capsules (typically 10–30 mg per capsule)
- Transdermal cream/gel (typically 15–30 mg per dose)
Dihexa is highly lipophilic, which means it absorbs well transdermally — unusual for a peptide. Both routes appear effective, with transdermal potentially offering smoother delivery and avoiding first-pass metabolism.
Research Dosing Reference
| Experience Level | Dose | Route | Frequency | Cycle |
|---|---|---|---|---|
| Beginner | 10 mg | Oral or transdermal | Every other day | 2 weeks on, 2 weeks off |
| Intermediate | 15–20 mg | Oral or transdermal | Daily (morning) | 3 weeks on, 2 weeks off |
| Advanced | 20–30 mg | Transdermal preferred | Daily (morning) | 4 weeks on, 3–4 weeks off |
Important Dosing Notes
- Long half-life: Dihexa has an estimated half-life measured in days, not hours. Effects accumulate over time. Do not increase dose rapidly — wait at least 3–4 days before assessing response.
- Morning-only dosing: Due to the long half-life and potential cognitive stimulation, administer in the morning only.
- Transdermal application sites: Inner forearm, upper arm, or back of the knee for transdermal use. Rotate sites to avoid local irritation.
- Do not stack with other HGF pathway activators without expert guidance.
Who Should Use Dihexa?
Strong Candidates
- Individuals experiencing age-related cognitive decline who want neurotrophic support beyond standard supplements
- Researchers interested in the most potent pro-synaptogenic compound currently available
- Those who have plateaued on other nootropic approaches and want to explore a structurally distinct mechanism
- Individuals with family history of Alzheimer's seeking preventive neurological support (in consultation with a physician)
Not Recommended For
- Individuals with a personal history of cancer (any type) — until more human safety data exists
- Pregnant or breastfeeding women
- Those under 25 (developing brain, unclear implications of exogenous synaptogenesis stimulus)
- Individuals seeking stimulant-type effects — Dihexa does not provide this
Dihexa vs Other Cognitive Peptides: Quick Comparison
| Peptide | Primary Mechanism | Effect Speed | Duration | Evidence Level |
|---|---|---|---|---|
| Dihexa | HGF/c-Met, synaptogenesis | Slow (days–weeks) | Long-lasting | Animal models, no human trials |
| Semax | BDNF upregulation, dopamine/serotonin | Fast (20–40 min) | Hours–days | Human clinical trials (Russia) |
| Selank | GABA-A, serotonin, enkephalins | Fast (20–30 min) | Hours | Human clinical trials (Russia) |
| Cerebrolysin | Multiple neurotrophic factors (BDNF, NGF, CNTF) | Days (IV/IM only) | Long-lasting | Extensive human clinical trials |
| BPC-157 | Growth hormone receptor, angiogenesis | Moderate (hours–days) | Days–weeks | Animal models, limited human data |
For a detailed Dihexa vs Cerebrolysin comparison, see our full comparison guide.
Is Dihexa Legal in the UAE?
Dihexa is not a controlled substance in the UAE. It does not appear on the UAE Federal Drug Control Law Schedule of Controlled Substances or any Ministry of Health prohibited substances list. It is not a steroid, stimulant, hormone, or controlled psychoactive. It is classified as a research chemical and is legal to purchase and possess in the UAE for personal research purposes.
As with all research peptides, it is sold with the designation "for research use only" and is not approved as a medicine in the UAE or elsewhere. UAE residents who purchase Dihexa for research purposes do so within the same regulatory framework as other research peptides available on this site.
Buy Research-Grade Dihexa in the UAE
CoreSup stocks Dihexa in oral capsule and transdermal forms — third-party tested with full certificates of analysis. Delivered across UAE within 2–3 business days.
Shop Dihexa at CoreSupFrequently Asked Questions
How long does Dihexa take to work?
Unlike fast-acting nootropics such as Semax or caffeine, Dihexa's effects build gradually over days to weeks. Most users report noticeable cognitive improvements — improved memory consolidation, enhanced learning speed, clearer thinking — after 1–3 weeks of consistent use. The compound has a very long estimated half-life, so effects accumulate rather than peak and trough daily.
Does Dihexa cause cancer?
There is no documented evidence that Dihexa causes cancer in humans — no human trials have been conducted. The concern is theoretical: Dihexa activates the HGF/c-Met pathway, which is dysregulated in some cancers. At normal research doses in healthy tissue, this pathway is regulated differently than in malignant tissue. However, individuals with a cancer history should not use Dihexa without medical consultation, as a precaution.
Can Dihexa be stacked with Semax?
Yes — Dihexa (HGF/c-Met, synaptogenesis) and Semax (BDNF, dopamine/serotonin) target different and complementary pathways. This is actually one of the most rationally designed cognitive peptide stacks available. Start each compound individually before combining, and keep doses on the conservative end when stacking. See our Semax + Dihexa stack guide for full protocol details.
What is the difference between Dihexa and Fosgonimeton?
Fosgonimeton (ATH-1017) is a pro-drug developed by Athira Pharma that is converted in the body to a compound targeting the same HGF/c-Met pathway as Dihexa. It has entered human clinical trials for Alzheimer's disease. Dihexa itself has not been in human trials. Fosgonimeton represents pharmaceutical validation of the pathway — confirming that the science behind Dihexa is considered credible by the broader research community.
Oral vs transdermal Dihexa — which is better?
Both routes are used by researchers. Transdermal delivery avoids first-pass liver metabolism and may produce a smoother, more sustained blood level — potentially advantageous given Dihexa's long half-life. Oral capsules are more convenient and have more user-reported data. Many researchers start with oral and transition to transdermal. Neither form is definitively superior; choose based on your practical preference and tolerance.
